Special issues in pediatric Hodgkin's disease

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 55-62

  Schwartz, Cindy L ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Adolescent; Hodgkin's disease; Late effects; Pediatric; Response based therapy

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RAZOXANE; VINBLASTINE; VINCRISTINE;

ACUTE HEART INFARCTION; ALGORITHM; ATHEROSCLEROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CARDIOTOXICITY; CELL TYPE; CHILD; CHILDHOOD CANCER; COLORECTAL CANCER; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; GONADAL DISEASE; GROWTH RETARDATION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYPOPLASIA; HYPOTHYROIDISM; LEUKEMIA; LUNG CANCER; LUNG TOXICITY; MEDICAL LITERATURE; MEDICAL SPECIALIST; METASTASIS; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN DISEASE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; SKIN CANCER; STOMACH CANCER; THYROID CANCER; TREATMENT PLANNING;

EID: 84900399082     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00456.x     Document Type: Conference Paper

References (80)

1. DIEHL V, FRANKLIN J, PFREUNDSCHUH M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
2. HORNING SJ, HOPPE RT, BRESLIN S, BARTLETT NL, BROWN BW, ROSENBERG SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
3. NACHMAN JB, SPOSTO R, HERZOG P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
4. CLEARY SF, LINK MP, DONALDSON SS. Hodgkin's disease in the very young. Int J Radiat Oncol Biol Phys 1994;28:77-83.
5. LEVANTHAL BGDS. Hodgkin's disease. In: PIZZO PAPD, ed. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott, 1989:457.
6. GLASER SL, LIN RJ, STEWART SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70:375-382.
7. AMBINDER RF, BROWNING PJ, LORENZANA I, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood 1993;81:462-467.
8. ANDRIKO JA, AGUILERA NS, NANDEDKAR MA, ABBONDANZO SL. Childhood Hodgkin's disease in the United States: an analysis of histologic subtypes and association with Epstein-Barr virus. Mod Pathol 1997;10:366-371.
9. JARRETT RF, KRAJEWSKI AS, ANGUS B, et al. The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates. J Clin Pathol 2003;56:811-816.
10. GRUFFERMAN SGG, POLLOCK BH, TAYLOR GM, SCHWARTZ CL, AMBINDER RF. Socioeconomic status, the Epstein-Barr virus and risk of Hodgkin's disease in chldren. Leuk Lymphoma 2001;42(Suppl. 2):40.
11. GLASER SL, CLARKE CA, KEEGAN TH, et al. Attenuation of social class and reproductive risk factor associations for Hodgkin lymphoma due to selection bias in controls. Cancer Causes Control 2004;15:731-739.
12. GLASER SL, CLARKE CA, NUGENT RA, STEARNS CB, DORFMAN RF. Reproductive factors in Hodgkin's disease in women. Am J Epidemiol 2003;158:553-563.
13. GLASER SL, CLARKE CA, NUGENT RA, STEARNS CB, DORFMAN RF. Social class and risk of Hodgkin's disease in young-adult women in 1988-94. Int J Cancer 2002;98: 110-117.
14. CHANG ET, ZHENG T, WEIR EG, et al. Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2004;13:1361-1370.
15. KARAYALCIN G, BEHM FG, GIESER PW, et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment - the Pediatric Oncology Group experience. Med Pediatr Oncol 1997;29:519-525.
16. SANDOVAL C, VENKATESWARAN L, BILLUPS C, SLIM M, JAYABOSE S, HUDSON MM. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002;24:269-273.
17. VAN DEN BERG A, MAGGIO E, DIEPSTRA A, DE JONG D, VAN KRIEKEN J, POPPEMA S. Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma. Blood 2002;99:1492-1494.
18. MIETTINEN M, FRANSSILA KO, SAXEN E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983;51:2293-2300.
19. HANSMANN ML, ZWINGERS T, BOSKE A, LOFFLER H, LENNERT K. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984;108:321-330.
20. PELLEGRINO B, TERRIER-LACOMBE MJ, OBERLIN O, et al. Lymphocyte- predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection - a study of the French Society of Pediatric Oncology. J Clin Oncol 2003;21:2948-2952.
21. MURPHY SB, MORGAN ER, KATZENSTEIN HM, KLETZEL M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003;25:684-687.
22. SCHELLONG G, POTTER R, BRAMSWIG J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
23. WOLDEN SL, LAMBORN KR, CLEARY SF, TATE DJ, DONALDSON SS. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536-544.
24. PROBERT JC, PARKER BR, KAPLAN HS. Growth retardation in children after megavoltage irradiation of the spine. Cancer 1973;32:634-639.
25. MAUCH PM, WEINSTEIN H, BOTNICK L, BELLI J, CASSADY JR. An evaluation of long-term survival and treatment complications in children with Hodgkin's disease. Cancer 1983;51:925-932.
26. DONALDSON SS, KAPLAN HS. Complications of treatment of Hodgkin's disease in children. Cancer Treat Rep 1982;66:977-989.
27. MERCHANT TE, NGUYEN L, NGUYEN D, WU S, HUDSON MM, KASTE SC. Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:556-561.
28. CONSTINE LS, DONALDSON SS, MCDOUGALL IR, Cox RS, LINK MP, KAPLAN HS. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 1984;53:878-883.
29. SKLAR C, WHITTON J, MERTENS A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227-3232.
30. HANCOCK SL, DONALDSON SS, HOPPE RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1208-1215.
31. BHATIA S, ROBISON LL, OBERLIN O, GREENBERG M, BUNIN G, FOSSATI-BELLANI F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
32. BHATIA S, YASUI Y, ROBISON LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-4394.
33. METAYER C, LYNCH CF, CLARKE EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18:2435-2443.
34. ALEMAN BM, KLOKMAN WJ, VAN LEEUWEN FE. Second primary tumors in patients treated at an early age for Hodgkin's disease; consequences for the follow-up. Ned Tijdschr Geneeskd 2000;144:1517-1520.
35. ALEMAN BM, VAN DEN BELT-DUSEBOUT AW, KLOKMAN WJ, VAN'T VEER MB, BARTELINK H, VAN LEEUWEN FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-3439.
36. NG AK, BERNARDO MP, WELLER E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-2108.
37. TRAVIS LB, CURTIS RE, BENNETT WP, HANKEY BF, TRAVIS WD, BOICE JD. Lung cancer after Hodgkin's disease. J Natl Cancer Inst 1995;87:1324-1327.
38. VAN LEEUWEN FE, KLOKMAN WJ, HAGENBEEK A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-325.
39. VAN LEEUWEN FE, KLOKMAN WJ, STOVALL M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:97I-980.
40. TRAVIS LB, HILL DA, DORES GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290: 465-475.
41. GLATSTEIN E, MCHARDY-YOUNG S, BRAST N, ELTRINGHAM JR, KRISS JP. Alterations in serum thyrotropin (TSH) and thyroid function following radiotherapy in patients with malignant lymphoma. J Clin Endocrinol Metab 1971;32: 833-841.
42. SCHIMPFF SC, DIGGS CH, WISWELL JG, SALVATORE PC, WIERNIK PH. Radiation-related thyroid dysfunction: implications for the treatment of Hodgkin's disease. Ann Intern Med 1980;92:91-98.
43. GREEN DM, BRECHER ML, YAKAR D, et al. Thyroid function in pediatric patients after neck irradiation for Hodgkin disease. Med Pediatr Oncol 1980;8:127-136.
44. HANCOCK SL, TUCKER MA, HOPPE RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-1955.
45. DONALDSON SS, HUDSON MM, LAMBORN KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002;20:3081-3087.
46. MACKIE EJ, RADFORD M, SHALET SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996;27:74-78.
47. KALDOR JM, DAY NE, CLARKE EA, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7-13.
48. THOMSON AB, WALLACE WH. Treatment of paediatric Hodgkin's disease. A balance of risks. Eur J Cancer 2002;38:468-477.
49. ORTIN TT, SHOSTAK CA, DONALDSON SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873-880.
50. VAN DEN BERG H, FURSTNER F, VAN DEN Bos C, BEHRENDT H. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2004;42:210-215.
51. HOBBIE WL, SCHWARTZ CL. Endocrine late effects among survivors of cancer. Semin Oncol Nurs 1989;5:14-21.
52. BOKEMEYER C, SCHMOLL HJ, VAN RHEE J, KUCZYK M, SCHUPPERT F, POLIWODA H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994;68:105-110.
53. BRAMSWIG JH, HEIMES U, HEIERMANN E, SCHLEGEL W, NIESCHLAG E, SCHELLONG G. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 1990;65:1298-1302.
54. SCHELLONG G, HORNIG I, BRAMSWIG J, et al. Significance of procarbazine in the chemotherapy of Hodgkin's disease - a report of the Cooperative Therapy Study DAL-HD-85. Klin Padiatr 1988;200:205-213.
55. DORFFEL W, LUDERS H, RUHL U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003;215:139-145.
56. SCHWARTZ CLTC, CONSTINE LS, MENDENHALL N, LONDON W, CHAUVENET A. Response based therapy for pediatric Hodgkin's disease: Pediatric Oncology Group (POG) Protocols 9425/9426. Med Pediatr Oncol 2001;37.
57. SCHELLONG G, BRAMSWIG JH, HORNIG-FRANZ I. Treatment of children with Hodgkin's disease - results of the German Pediatric Oncology Group. Ann Oncol 1992;3(Suppl. 4):73-76.
58. ANDRIEU JM, OCHOA-MOLINA ME. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease. Cancer 1983;52:435-438.
59. KOYAMA H, WADA T, NISHIZAWA Y, IWANAGA T, AOKI Y. Cyclophosphamide- induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-1409.
60. BYRNE J, FEARS TR, GAIL MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793.
61. BEATY O III, HUDSON MM, GREENWALD C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995;13:603-609.
62. BLAYNEY DW, LONGO DL, YOUNG RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-714.
63. TUCKER MA, COLEMAN CN, COX RS, VARGHESE A, ROSENBERG SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81.
64. MARINA NM, GREENWALD CA, FAIRCLOUGH DL, et al. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 1995;75:1706-1711.
65. FRYER CJ, HUTCHINSON RJ, KRAILO M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. J Clin Oncol 1990;8:1971-1980.
66. HUNGER SP, LINK MP, DONALDSON SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol 1994;12:2160-2166.
67. HUDSON MM, GREENWALD C, THOMPSON E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993;11:100-108.
68. OBERLIN O, LEVERGER G, PACQUEMENT H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602-1608.
69. WEINER MA, LEVENTHAL BG, MARCUS R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1991;9:1591-1598.
70. CANELLOS GP, ANDERSON JR, PROPERT KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
71. HUDSON MM, DONALDSON SS. Treatment of pediatric Hodgkin's lymphoma. Semin Hematol 1999;36:313-323.
72. LANDMAN-PARKER J, PACQUEMENT H, LEBLANC T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000;18:1500-1507.
73. KELLY KM, HUTCHINSON RJ, SPOSTO R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 2002;13(Suppl. 1):107-111.
74. RUHL U, ALBRECHT M, DIECKMANN K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001;51:1209-1218.
75. KUNG FHCA, FERREE CR, CANTOR AB, GEISER P, ZABANEH A. Late effects on pulmonary function in children with early stage Hodgkin's disease treated with reduced dose chemoradiotherapy. Proc Annu Meet Am Soc Clin Oncol 1996;15:A1332.
76. BONADONNA G, SANTORO A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982;9:21-35.
77. DE VITA VTSA, CARBONE PP. Combination therapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895.
78. TEBBI CKMN, SCHWARTZ C, WILLIAMS J, et al. Response dependent treatment of stages IA, ILA, and III A1micro Hodgkin's disease with DBVE and low dose involved field irradiation with or without dexrazoxane. Leuk Lymphoma 2001;42(Suppl. 2):100.
79. FRIEDMANN AM, HUDSON MM, WEINSTEIN HJ, et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 2002;20:3088-3094.
80. BARTLETT NL, ROSENBERG SA, HOPPE RT, HANCOCK SL, HORNING SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-1088.